+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anti-Asthmatics and COPD Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030

  • PDF Icon

    Report

  • April 2021
  • Region: Global
  • The Business Research Company
  • ID: 5319080
Anti-Asthmatics And COPD Drugs Global Market Report 2021: COVID-19 Implications And Growth to 2030 covers this critical market and the impact on it from the COVID-19 virus. It provides strategists, marketers and senior management with the critical information they need to assess the increasing demand for anti-asthmatics and copd drugs due to COVID-19.







Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:

Where is the largest and fastest growing market for the anti-asthmatics and copd drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Anti-Asthmatics And COPD Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:
1) By Drug Class: Bronchodilators ; Anti-inflammatory Drugs; Monoclonal Antibodies; Combination Drugs
2) By End User: Asthma Patients; COPD Patients
3) By Distribution Channel: Hospital Pharmacies ; Private Clinics ; Drug Stores ; Retail Pharmacies ; E-Commerce

Companies Mentioned: Novartis AG; Merck & Co; GlaxoSmithKline ; Boehringer Ingelheim Gmbh; AstraZeneca

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Frequently Asked Questions about the Global Anti-Asthmatics and Copd Drugs Market

What is the estimated value of the Global Anti-Asthmatics and Copd Drugs Market?

The Global Anti-Asthmatics and Copd Drugs Market was estimated to be valued at $66.8 billion in 2021.

What is the growth rate of the Global Anti-Asthmatics and Copd Drugs Market?

The growth rate of the Global Anti-Asthmatics and Copd Drugs Market is 6.7%, with an estimated value of $86.4 billion by 2025.

What is the forecasted size of the Global Anti-Asthmatics and Copd Drugs Market?

The Global Anti-Asthmatics and Copd Drugs Market is estimated to be worth $86.4 billion by 2025.

Who are the key companies in the Global Anti-Asthmatics and Copd Drugs Market?

Key companies in the Global Anti-Asthmatics and Copd Drugs Market include Novartis AG, Merck & Co, GlaxoSmithKline, Boehringer Ingelheim Gmbh, AstraZeneca, Roche, Teva Pharmaceutical, Vectura and Abbott.

Table of Contents

1. Executive Summary2. Anti-Asthmatics And COPD Drugs Market Characteristics3. Anti-Asthmatics And COPD Drugs Market Trends And Strategies4. Impact Of COVID-19 on Anti-Asthmatics And COPD Drugs
5. Anti-Asthmatics And COPD Drugs Market Size And Growth
5.1. Global Anti-Asthmatics And COPD Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers of the Market
5.1.2. Restraints on The Market
5.2. Global Anti-Asthmatics And COPD Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers of the Market
5.2.2. Restraints on the Market
6. Anti-Asthmatics And COPD Drugs Market Segmentation
6.1. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Bronchodilators
  • Anti-inflammatory Drugs
  • Monoclonal Antibodies
  • Combination Drugs
6.2. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Asthma Patients
  • COPD Patients
6.3. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Private Clinics
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce

7. Anti-Asthmatics And COPD Drugs Market Regional And Country Analysis
7.1. Global Anti-Asthmatics And COPD Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Anti-Asthmatics And COPD Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8. Asia-Pacific Anti-Asthmatics And COPD Drugs Market
8.1. Asia-Pacific Anti-Asthmatics And COPD Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
9. China Anti-Asthmatics And COPD Drugs Market
9.1. China Anti-Asthmatics And COPD Drugs Market Overview
9.2. China Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
10. India Anti-Asthmatics And COPD Drugs Market
10.1. India Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11. Japan Anti-Asthmatics And COPD Drugs Market
11.1. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Australia Anti-Asthmatics And COPD Drugs Market
12.1. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13. Indonesia Anti-Asthmatics And COPD Drugs Market
13.1. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14. South Korea Anti-Asthmatics And COPD Drugs Market
14.1. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15. Western Europe Anti-Asthmatics And COPD Drugs Market
15.1. Western Europe Anti-Asthmatics And COPD Drugs Market Overview
15.2. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16. UK Anti-Asthmatics And COPD Drugs Market
16.1. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17. Germany Anti-Asthmatics And COPD Drugs Market
17.1. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18. France Anti-Asthmatics And COPD Drugs Market
18.4. France Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19. Eastern Europe Anti-Asthmatics And COPD Drugs Market
19.1. Eastern Europe Anti-Asthmatics And COPD Drugs Market Overview
19.2. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20. Russia Anti-Asthmatics And COPD Drugs Market
20.1. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21. North America Anti-Asthmatics And COPD Drugs Market
21.1. North America Anti-Asthmatics And COPD Drugs Market Overview
21.2. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22. USA Anti-Asthmatics And COPD Drugs Market
22.1. USA Anti-Asthmatics And COPD Drugs Market Overview
22.2. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23. South America Anti-Asthmatics And COPD Drugs Market
23.1. South America Anti-Asthmatics And COPD Drugs Market Overview
23.2. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24. Brazil Anti-Asthmatics And COPD Drugs Market
24.1. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25. Middle East Anti-Asthmatics And COPD Drugs Market
25.1. Middle East Anti-Asthmatics And COPD Drugs Market Overview
25.2. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26. Africa Anti-Asthmatics And COPD Drugs Market
26.1. Africa Anti-Asthmatics And COPD Drugs Market Overview
26.2. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
27. Anti-Asthmatics And COPD Drugs Market Competitive Landscape And Company Profiles
27.1. Anti-Asthmatics And COPD Drugs Market Competitive Landscape
27.2. Anti-Asthmatics And COPD Drugs Market Company Profiles
27.2.1. Novartis AG
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Merck & Co
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. GlaxoSmithKline
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Boehringer Ingelheim Gmbh
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. AstraZeneca
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Anti-Asthmatics And COPD Drugs Pipeline Analysis29. Key Mergers And Acquisitions In The Anti-Asthmatics And COPD Drugs Market30. Anti-Asthmatics And COPD Drugs Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the anti-asthmatics and chronic obstructive pulmonary disease (COPD) market are Novartis AG, Merck & Co, GlaxoSmithKline, Boehringer Ingelheim Gmbh and AstraZeneca.

The global anti-asthmatics and copd drugs market is expected to decline from $75.38 billion in 2020 to $66.81 billion in 2021 at a compound annual growth rate (CAGR) of -11.4%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $86.44 billion in 2025 at a CAGR of 6.7%.

The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market consists of sales of anti-asthmatics and chronic obstructive pulmonary disease (COPD) drugs which are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings. The class of drugs includes Bronchodilators, anti-inflammatory drugs, monoclonal antibodies and combination drugs.

Developing the patent expiration of innovator drugs is restricting the anti-asthmatics and COPD drug market. Due to patent expiration, generic drugs are entering the market which is inexpensive when compared to innovator drugs. For example, the patent for roflumilast tablets expired in January 2020. Daliresp, roflumilast tablets are a prescription medication meant for patients with severe COPD to reduce the number of episodes of COPD. The FDA originally approved Daliresp in May 2011, and the drug had a market value of $211 million for the fiscal year ended August 31, 2018.
The use of combination drugs for the treatment of asthma and COPD is increasing. This is due to the greater impact on patient reported outcomes (PROs) compared to monotherapies. For example, combination of short acting beta agonists (SABA) and short acting muscarinic antagonists (SAMA) are superior compared to either medication alone in improving lung function. The use of combination long acting beta agonists (LABA), and long acting muscarnic antagonists (LAMA) have improved lung function than long acting monotherapy bronchodilators.

Many inhalers that do not use chlorofluorocarbons (CFC) are already available for the treatment of asthma and chronic obstructive pulmonary disease. These products aren't necessarily """"official"""" direct alternatives to CFC Metered Dose Inhalers, but may in many patients serve as a useful medication that could replace the need for a particular CFC Metered Dose Inhaler. FDA will determine official alternatives by using the criteria established through notice-and-comment rulemaking.

Modifiable risk factors including smoking, lack of physical exercise, and unhealthy eating habits drive the Asthma and COPD drugs market. Even though there is a decreasing trend of smoking prevalence globally, developing countries such as China, India, Indonesia, and Nigeria among others have increasing smoking prevalence. For instance, the number of tobacco smokers is set to increase by 24 million in Indonesia and by 7 million in Nigeria from 2015 to 2025, and more than 40% of global cigarette consumption is concentrated in China. Consumption of fats including saturated fatty acids which is a risk factor for Asthma and COPD is more in high income countries including USA and Europe. According to WHO, in developed countries more than 35% of total energy requirement is derived from fats when compared to < 20% in low income countries, and < 25% in lower middle income countries.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Novartis AG
  • Merck & Co
  • GlaxoSmithKline
  • Boehringer Ingelheim Gmbh
  • AstraZeneca
  • Roche
  • Teva Pharmaceutical
  • Vectura
  • Pfizer
  • Abbott
  • Mylan
  • Allergan
  • Cipla
  • Akorn

Methodology

Loading
LOADING...